bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.03.06.641923

Genome-scale metabolic modeling and machine learning unravel metabolic reprogramming and mast cell role in lung cancer through a multi-level analysis

Abstract

Lung cancer remains a leading cause of cancer-related deaths worldwide, with immune interactions, particularly involving mast cells, playing a crucial role. Mast cells contribute to both pro- and anti-tumorigenic activities, influencing immune modulation, angiogenesis, and tissue remodeling. This study provides a comprehensive multi-level analysis of metabolic alterations in lung cancer through genome-scale metabolic modeling (GSM) and machine learning. Using 43 paired lung tissue samples, we developed metabolic models of lung cancer and mast cells, revealing a significant reduction in resting mast cells in cancerous tissues. Our Random Forest classifier accurately distinguished between healthy and cancerous states, identifying key metabolic signatures. We found that lung cancer cells selectively upregulate valine, isoleucine, histidine, and lysine metabolism in the aminoacyl-tRNA pathway to support their elevated energy demands. Mast cell metabolism exhibited enhanced histamine transport and increased glutamine consumption in the tumor microenvironment, suggesting a shift towards immunosuppressive activity. Additionally, our novel Metabolic Thermodynamic Sensitivity Analysis (MTSA) showed impaired biomass production in cancerous mast cells across physiological temperatures (36 to 40C), indicating metabolic vulnerabilities. By elucidating the metabolic adaptations of mast cells and lung cancer cells, our study highlights their interplay in tumor progression and identifies potential therapeutic targets and diagnostic markers for future investigation. Author SummaryOur research examines the intricate relationship between lung cancer and mast cells, a type of immune cell, using advanced computational methods. We developed detailed metabolic models of lung tissue and mast cells through a multi-level approach to understand how their metabolism changes in cancer. Our findings reveal that lung cancer cells modify their metabolic pathways to meet increased energy demands, including enhanced utilization of four specific amino acids within the aminoacyl-tRNA pathway. In addition, mast cells in lung cancer environments show increased histamine release and glutamine consumption, suggesting they become more active in ways that might promote tumor growth. Additionally, we found that cancerous mast cells are less able to adapt to temperature changes compared to healthy ones, which could impact how they respond during fever or inflammation. These insights provide new perspectives on how lung cancer affects the immune system and could lead to novel approaches for diagnosis and treatment. By understanding these complex interactions, we aim to contribute to the development of more effective strategies for combating lung cancer.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Tabibian, M., Razmpour, T., Saha, R.. 2025-03-07. Genome-scale metabolic modeling and machine learning unravel metabolic reprogramming and mast cell role in lung cancer through a multi-level analysis. https://doi.org/10.1101/2025.03.06.641923

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ex vivo human tumor slices more accurately predict patient responses to an oncolytic virus than in vivo mouse models

Immunotherapies, including oncolytic viruses (OV), are promising therapies that can enhance anti-tumor immune responses. However, preclinical success of immunotherapies in mouse models has not always translated to clinical benefit in cancer patients. This study compared preclinical efficacy and mechanism of action for ASP9801, a vaccinia virus expressing IL-7 and IL-12, using mouse models of colorectal cancer (CRC) in vivo and in human organotypic tumor slice models ex vivo. The murine surrogate for ASP9801 significantly reduced tumor volumes in treated and abscopal tumors in two different CRC models in vivo (MC38 and RO100). Treatment efficacy was accentuated when combined with anti-PD1 treatment, and single-cell RNA sequencing analysis revealed depletion of tumor cells and increased T cell infiltration and activation in both treated and abscopal tumors. However, human tissue analysis ex vivo (E-slices) using PDX models and patient samples showed that ASP9801 is not effective in CRC, consistent with clinical trial results. On the other hand, ASP9801 was highly effective in GBM, indicating indication-specific efficacy of ASP9801, and how E-slice assays can be used to identify treatment-sensitive indications. This study demonstrates the superiority of E-slices over mouse models for predicting clinical response and its utility in planning clinical trials.

cancer biology↗

Immune-cell depleted diffuse large B-cell lymphomas have reduced expression of MHC class I

Immunotherapy has transformed treatment for many cancers. In the aggressive and genetically heterogeneous diffuse large B-cell lymphoma (DLBCL), CD19 CAR T-cell therapy is highly effective, whereas immune checkpoint blockade has shown limited benefit. Loss of MHC expression is a common mechanism to escape T-cell cytotoxicity, and loss of MHC class I (MHC-I) and II are frequent in DLBCL. We applied imaging mass cytometry to diagnostic biopsies from younger, high-risk DLBCL patients to map the tumor microenvironment (TME) spatial architecture in relation to tumor cell MHC expression, mutational status, transcriptomic and proteomic profiles. Neighborhood analyses identified four TME subtypes: immune-cell depleted and three immune-infiltrated types (mixed, CD4 T cell-rich, CD8 T-cell/macrophage-rich). Depleted cases had shorter overall survival (p = 0.033) and increased expression of proteins involved in DNA replication and proliferation markers compared to infiltrated cases. Tumor cell MHC-I expression was heterogeneous. Cases with low frequency of MHC-I-pos tumor cells were enriched for the depleted TME type. MHC-I-pos tumor cells were surrounded by CD4 and CD8 T cells and M1 macrophages, whereas MHC-I-neg tumor cells were closer to other MHC-I-neg tumor cells. These findings suggest that TME-based classification incorporating tumor cell MHC-I status may improve individualized immunotherapy selection.

cancer biology↗

Cross-species analysis links cell-cell communication rewiring to NOTCH2 during serous endometrial carcinogenesis

Cell-cell interactions shape the fate of mutant cells during cancer initiation but how these interactions evolve during progression to pathologically recognizable lesions remain poorly understood. Here, we investigated cell-cell communication during serous endometrial carcinoma (SEC; also known as uterine serous carcinoma) development using a lineage-traceable mouse model and cross-species analyses of the mouse and human neoplastic endometrium. In mice, the early, pre-dysplastic stage was marked by a global decrease in inferred cell-cell interactions, followed by extensive communication network rewiring during neoplastic progression. Pathway-specific analysis revealed a similar pattern for NOTCH signaling, with NOTCH2 emerging as the dominant NOTCH receptor in Trp53/Rb1-mutant immature epithelial cells. Functionally, NOTCH2 promoted the outgrowth of more proliferative mutant organoids. Cross-species transcriptomic analysis identified conserved immature epithelial states in mouse and human neoplastic endometrial epithelium. In human tissues, NOTCH2 was overexpressed in serous endometrial intraepithelial carcinoma, a precursor of SEC, and in overt SEC. Furthermore, elevated NOTCH2 expression was associated with poor patient survival. These findings link cell-cell communication rewiring during experimental SEC development to conserved neoplastic epithelial states and identify NOTCH2 as an early marker and a potential target of disease interception.

cancer biology↗